Search results for "ADJUVANT CHEMOTHERAPY"

showing 10 items of 53 documents

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

2005

Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role …

Oncologystage IIIA-N2medicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentDocetaxelNSCLCDeoxycytidinemolecular markers analysisCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineStage (cooking)Lung cancerNeoplasm StagingCisplatinChemotherapybusiness.industryInduction chemotherapyHematologymedicine.diseaseearly stageGemcitabineRadiation therapyneoadjuvant radiotherapyOncologyTolerabilityDocetaxelChemotherapy AdjuvantRadiotherapy AdjuvantTaxoidsCisplatinbusinessmedicine.drugneoadjuvant chemotherapy
researchProduct

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art

2022

: Ovarian cancer represents the fifth cause of cancer death among women, carrying one of the worst prognoses among gynaecological malignancies. The need to achieve no residual disease after surgery in order to optimize prognosis of advanced-stage ovarian cancer introduced the idea of neoadjuvant chemotherapy. The present review aims to summarize current state-of-the-art evidence regarding the efficacy and safety of neoadjuvant chemotherapy as well as novel insights regarding the usage of modern therapeutic regimens in the context of neoadjuvant chemotherapy. The last decade has been characterized by the breakthrough scientific evidence that neoadjuvant chemotherapy followed by interval debu…

PARP inhibitorOvarian cancerEndocrinology Diabetes and MetabolismObstetrics and Gynecologystate of the artDiagnostic laparoscopyNeoadjuvant chemotherapySettore MED/40 - Ginecologia E OstetriciaMenopausal Review
researchProduct

Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer

2023

Objective: To identify the best method among the radiologic, laparoscopic and laparotomic scoring assessment to predict the outcomes of cytoreductive surgery in patients with advanced ovarian cancer (AOC). Methods: Patients with AOC who underwent pre-operative computed tomography (CT) scan, laparoscopic evaluation, and cytoreductive surgery between August 2016 and February 2021 were retrospectively reviewed. Predictive Index (PI) score and Peritoneal Cancer Index (PCI) scores were used to estimate the tumor load and predict the residual disease in the primary debulking surgery (PDS) and interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) groups. Concordance percentages we…

Predictive index scoreCancer ResearchOncologyOvarian cancerPrediction modelCytoreductive surgeryPrimary debulking surgery.Interval debulking surgeryNeoadjuvant chemotherapyPeritoneal cancer index scoreSettore MED/40 - Ginecologia E Ostetriciaovarian cancer; cytoreductive surgery; prediction model; predictive index score; peritoneal cancer index score; primary debulking surgery; interval debulking surgery; neoadjuvant chemotherapyCancers
researchProduct

18F-FDG PET imaging of breast cancer : evaluation of the metabolic behaviour of the different breast cancer subtypes and prediction of the tumor resp…

2015

Positron Emission Tomography (PET) with 18Fluoro-deoxyglucose (18F-FDG) is the reference imaging examination for in-vivo quantification of the glucidic metabolism of tumour cells. It allows for the monitoring of tumour metabolic changes during chemotherapy. Breast cancer comprises several distinct genomic entities with different biological characteristics and clinical behaviours, leading to different tailored treatments. The aim of this doctoral thesis was to evaluate the relationship between the different biological entities of breast cancer and the tumour metabolic behaviour during neoadjuvant chemotherapy. We have also retrieved, among the various metabolic parameters on PET images, the …

Subtypes[SDV.IB] Life Sciences [q-bio]/BioengineeringFDGPositon EmissionTomographyRéponse tumoraleNeoadjuvant chemotherapyPhénotypesPETBreast cancerTEP[SDV.CAN] Life Sciences [q-bio]/CancerÉvaluationTomographie par Emission de PositonChimiothérapie néoadjucanteTumor responseCancer du sein[SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing
researchProduct

Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer

2012

Objective: The aim of this study is to assess our results of treatment of women with stage I cervical cancer > 2 cm in diameter seeking fertility preservation. Treatment consisted of Laparoscopic Pelvic and Paraaortic Lymphadenectomy (LPPLND), and when no nodal metastasis was detected, neoadjuvant chemotherapy (NACT) followed by radical vaginal trachelectomy (RVT). Patients with positive lymph nodes underwent primary chemoradiation. Methods: A cohort of women younger than 40 years of age with stage I disease > 2 cm who underwent LPPLND and either NACT and RVT or chemoradiation. Oncological outcome was evaluated prospectively. Results: Eighteen women were eligible for this study. Twelve (67%…

Uterine Cervical NeoplasmRVTmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCervix UteriMetastasisParaaortic lymph nodesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesFertility preservationProspective cohort studyLymph nodeNeoadjuvant therapyCervical cancerFertility PreservationObstetrics and GynecologyChemoradiotherapyNeoadjuvant Therapymedicine.anatomical_structureOncologyChemotherapy AdjuvantLymphatic MetastasisCarcinoma Squamous CellFemaleRadiologyHumanAdultmedicine.medical_specialtyPaclitaxelPelviRadical vaginal trachelectomyCervical carcinoma; Radical vaginal trachelectomy; Neoadjuvant chemotherapyAdenocarcinomaNeoadjuvant chemotherapyPelvisFollow-Up StudieHumansIfosfamideCervical carcinomaNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryGeneral surgeryLymphatic Metastasimedicine.diseaseProspective StudieLymph Node ExcisionLaparoscopyCisplatinNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Clinical Recommendation Radical Trachelectomy for Fertility Preservation in Patients With Early-Stage Cervical Cancer

2012

Radical trachelectomy (RT) is a fertility-sparing procedure with the aim to provide adequate oncological safety to patients with cervical cancer while preserving their fertility. In the current review, indications, development of the procedure, technical aspects, preoperative and postoperative management, and oncological, fertility, and obstetric outcomes are discussed and studied with respect to whether the procedure is performed abdominally or vaginally. Complications of RT, staging, and more conservative alternatives to RT are discussed as well. A systematic MEDLINE search was performed, which yielded 218 articles, of which 75 were selected for further analysis based on the number of pat…

Uterine Cervical Neoplasmmedicine.medical_specialtyCervical cancer; Radical trachelectomy; Fertility preservationPrognosimedia_common.quotation_subjectmedicine.medical_treatmentUterine Cervical NeoplasmsTrachelectomyFertilityHysterectomyNeoadjuvant chemotherapyRadical trachelectomy03 medical and health sciences0302 clinical medicineAbdominal radical trachelectomymedicineHumansFertility preservationStage (cooking)CervixNeoadjuvant therapyOutcomeNeoplasm Stagingmedia_commonCervical cancerVaginal radical trachelectomy030219 obstetrics & reproductive medicineHysterectomybusiness.industryGeneral surgeryFertility PreservationObstetrics and GynecologyPrognosismedicine.diseaseNeoadjuvant Therapy3. Good healthSurgerymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCervical cancerLymph Node ExcisionFemalebusinessHumanInternational Journal of Gynecological Cancer
researchProduct

Retrospektīvs pētījums par dzīvildzi resnās zarnas vēža II stadijā, atkarībā no ārstēšanas stratēģijas

2017

Ievads: Adjuvanta ķīmijterapija pacientiem ar diagnosticētu II (UICC) stadijas resnās zarnas vēzi ir apsverama. Pacientu dalījums augsta un zema riska grupās, palīdz izlemt, vai pēc ķirurģiskas ārstēšanas ir indicēta ķīmijterapija, lai gan dzīvildzes ieguvumi nav ne plaši pētīti, nedz arī pierādīti. Tāpēc, autora mērķis šajā pētījumā bija salīdzināt piecu gadu dzīvildzi UICC II stadijas resnās zarnas vēža pacientiem, kuri saņēma adjuvantu ķīmijterapiju, un pacientiem, kuri ķīmijterapiju nesaņēma. Metodes: Dati par pacientiem ar II stadijas resnās zarnas vēzi, tika iegūti Paula Stradiņa Klīniskās universitātes slimnīcā Rīgā, Latvijā, Onkoloģijas klīnikā. Diagnozes apstiprināšanas laiks no 20…

adjuvant chemotherapycolon cancer stage IIUICC IIoverall five-year survivalMedicīna
researchProduct

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer.

2022

Advances in the management of gastric cancer have improved patient survival in the last decade. Nonetheless, the number of patients relapsing and dying after a diagnosis of localized gastric cancer is still too high, even in early stages (10% in stage I). Adjuvant systemic chemotherapy has been proven to significantly improve outcomes. In the present article we have critically reviewed the clinical trials that guide the current clinical practice in the adjuvant treatment of patients affected by resectable gastric cancer, focusing on the different approaches worldwide, i.e., adjuvant chemotherapy, adjuvant chemoradiotherapy, and perioperative chemotherapy. We also delineate the clinical–path…

adjuvant chemotherapypredictive factorCancer ResearchOncologygastric cancerprognostic factors.Cancers
researchProduct

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

2021

Geburtshilfe und Frauenheilkunde 81(10), 1112-1120 (2021). doi:10.1055/a-1499-8431

medicine.medical_specialtyAxillary lymph nodesBreast surgerymedicine.medical_treatmentMammakarzinomBreast cancerbreast cancerMaternity and MidwiferyAdjuvant therapymedicineddc:610GebFra ScienceStage (cooking)Sentinel-Lymphknoten-Entfernungtargeted axillary dissectionsentinel LNEneoadjuvante Chemotherapiebusiness.industryObstetrics and Gynecologymedicine.diseaseRadiation therapyDissectionAxillamedicine.anatomical_structuregezielte axilläre DissektionRadiologybusinessRecommendation/Empfehlungneoadjuvant chemotherapy
researchProduct

1088 Minimally-invasive pelvic exenteration: a survival analysis

2021

Minimally-invasive pelvic exenteration: a survival analysis. Introduction/Background* Pelvic exenteration for recurrent and persistent gynecological malignancies is traditionally performed with open approach (OA). Nevertheless, reports on the use of minimally-invasive surgical (MIS) approach to pelvic exenteration have been published with promising results in terms of peri-operative morbidity. However, oncological safety of this approach has been poorly investigated. The aim of the present study was to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing minimally-invasive pelvic exenteration. Methodology All patients undergoing pelvic exenteration for gyn…

medicine.medical_specialtyMultivariate analysisSurgical approachPelvic exenterationbusiness.industryProportional hazards modelAdjuvant chemotherapymedicine.medical_treatmentSurgeryMedian follow-upMedicinebusinessGrading (tumors)Survival analysisMiscellaneous
researchProduct